Latest news with #RevolutionMedicines
Yahoo
16-07-2025
- Business
- Yahoo
Revolution Medicines (RVMD) Gets Initiated With a New Buy Rating at Goldman Sachs
Revolution Medicines, Inc. (NASDAQ:RVMD) is one of the best oversold NASDAQ stocks to buy now. On July 15, Goldman Sachs analyst Andrea Newkirk initiated a new Buy rating on Revolution Medicines, Inc. (NASDAQ:RVMD) with a $65 price target. A researcher poring over test results, illustrating the breakthrough potential of biotechnology. The analyst based the rating on the company's promising clinical developments and strategic focus, stating that Revolution Medicines, Inc. (NASDAQ:RVMD) is at the forefront of precision oncology. The company is focusing on a portfolio of RAS(On) inhibitors that treat RAS-addicted cancers, including pancreatic ductal adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC), and colorectal cancer (CRC). The analyst further stated that daraxonrasib is Revolution Medicines, Inc.'s (NASDAQ:RVMD) lead asset and is undergoing advanced clinical trials, such as two Phase 3 registrational trials for metastatic PDAC and NSCLC. Newkirk considers the potential of daraxonrasib, when used in combination with other therapies, to be quite promising, which may significantly increase its commercial success. Revolution Medicines, Inc. (NASDAQ:RVMD) is a clinical-stage precision oncology company that develops novel targeted therapies. It discovers and develops cancer treatments through novel combinations and monotherapy treatment regimens that enhance clinical benefits. While we acknowledge the potential of RVMD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
06-07-2025
- Business
- Yahoo
Revolution Medicines, Summit Therapeutics Partner on RAS Inhibitor/Ivonescimab Combinations for Solid Tumors
Revolution Medicines Inc. (NASDAQ:RVMD) is one of the best high short interest stocks with huge upside potential. On June 30, Revolution Medicines and Summit Therapeutics Inc. (NASDAQ:SMMT) announced a clinical collaboration to evaluate combinations of Revolution Medicines' investigational RAS(-ON) inhibitors with Summit Therapeutics' ivonescimab in multiple solid tumor settings. The collaboration will assess the safety and efficacy of these combinations in RAS mutant non-small cell lung cancer/NSCLC, pancreatic ductal adenocarcinoma/PDAC, and colorectal cancer/CRC. Under the agreement, Summit Therapeutics will supply ivonescimab for clinical research, while Revolution Medicines will serve as the study sponsor. Both companies will retain commercial rights to their respective compounds. A researcher poring over test results, illustrating the breakthrough potential of biotechnology. The agreement is mutually non-exclusive, allowing each company to pursue additional partnerships. Revolution Medicines will contribute 3 of its clinical-stage RAS(-ON) inhibitors to the collaboration: daraxonrasib (RMC-6236), which is a multi-selective inhibitor; zoldonrasib (RMC-9805), which is a G12D-selective inhibitor; and elironrasib (RMC-6291), which is a G12C-selective inhibitor. Revolution Medicines Inc. (NASDAQ:RVMD) is a clinical-stage precision oncology company that develops novel targeted therapies for RAS-addicted cancers. Summit Therapeutics Inc. (NASDAQ:SMMT) is a biopharmaceutical company. While we acknowledge the potential of RVMD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
03-07-2025
- Business
- Yahoo
Oppenheimer Reaffirms Outperform on Revolution Medicines, Cites PDAC and NSCLC Trial Progress
Revolution Medicines, Inc. (NASDAQ:RVMD) ranks among the 30 stocks expected to beat the market by 20 percentage points this year. Oppenheimer analysts maintained their $75 price target for Revolution Medicines, Inc. (NASDAQ:RVMD) and reaffirmed their Outperform rating on June 3. Updates from competing KRAS initiatives that were given at this year's ASCO meeting coincide with the reaffirmation. The Oppenheimer analysts pointed out that smaller datasets would provide difficulties for Revolution's rivals in the G12Di arena for pancreatic ductal adenocarcinoma (PDAC). That said, Revolution's Phase 3 trials in second-line and beyond are currently recruiting for PDAC and non-small cell lung cancer (NSCLC. With the initiation of registrational trials in the adjuvant context and first-line metastatic PDAC, focus is now turning to front-line prospects. Potential pipeline updates that could further inform Revolution's development plan are anticipated by the analysts for the second half of the year. Revolution Medicines, Inc. (NASDAQ:RVMD) is a clinical-stage biotech company that develops cancer medications that target RAS, a major category of genetic abnormalities that are frequently present in difficult-to-treat cancers. While we acknowledge the potential of RVMD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. Read More: and Disclosure: None.
Yahoo
26-06-2025
- Business
- Yahoo
Revolution Medicines partners Royalty Pharma on $2bn funding
Revolution Medicines has partnered Royalty Pharma for $2bn in flexible funding to support the independent worldwide development and commercialisation strategy of its renin-angiotensin system (RAS) oncogene (ON) inhibitors. The RAS(ON) inhibitor portfolio is targeted at patients with RAS-addicted cancers. The funding agreement comprises up to $1.25bn through synthetic royalty monetisation on sales of Revolution Medicines' RAS(ON) multi-selective inhibitor, daraxonrasib, and up to $750mn in corporate debt. Revolution will retain complete strategic and executional control over product development, along with commercialisation efforts both within the US and globally. Revolution Medicines CEO and chairman Mark Goldsmith stated: 'Today's announcement represents a major boost to our bold vision on behalf of patients with RAS-addicted cancers. 'This funding agreement significantly increases the financial resources we can deploy while preserving optionality as we scale our operations to create the industry-leading global targeted medicines franchise for patients with RAS-addicted cancers based on our highly differentiated RAS(ON) inhibitor portfolio.' Royalty Pharma is set to offer as much as $1.25bn in return for tiered royalties over 15 years based on the global annual net sales of daraxonrasib. The synthetic royalty component is structured into five $250m tranches. Revolution received an initial tranche from Royalty Pharma on completion. The second is contingent upon positive results from the company's Phase III RASolute 302 study targeting pancreatic ductal adenocarcinoma (PDAC). If zoldonrasib, another candidate in its pipeline, is approved for indications with daraxonrasib, its sales would contribute towards the total net sales subject to royalties under this agreement. However, if approved with exclusive indications for zoldonrasib, it would not incur royalty costs. The debt facility portion consists of three tranches totalling up to $750m linked directly to daraxonrasib's commercial milestones. The first tranche will be received by Revolution, following US Food and Drug Administration (FDA) approval of daraxonrasib to treat metastatic PDAC by January 2028. Subsequent tranches depend on the company's decision and will be made available after achieving specific annual net sales of daraxonrasib. "Revolution Medicines partners Royalty Pharma on $2bn funding" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Reuters
24-06-2025
- Business
- Reuters
Royalty Pharma to pay up to $2 billion to Revolution Medicines for cancer drug
June 24 (Reuters) - Royalty Pharma (RPRX.O), opens new tab said on Tuesday will pay up to $2 billion to Revolution Medicines (RVMD.O), opens new tab to support the companies' plans for global development and commercialization of the experimental cancer drug daraxonrasib.
